1. Enhancing Oocyte Quality in Aging Mice: Insights from Mesenchymal Stem Cell Therapy and FOXO3a Signaling Pathway Activation.
- Author
-
Wang L, Liu Y, Song Y, Mei Q, Mou H, Wu J, Tang X, Ai J, Li K, Xiao H, Han X, Lv L, Li H, Zhang L, and Xiang W
- Subjects
- Animals, Female, Mice, Mesenchymal Stem Cell Transplantation methods, Coculture Techniques, Granulosa Cells metabolism, Forkhead Box Protein O3 metabolism, Oocytes metabolism, Signal Transduction physiology, Aging physiology, Aging metabolism, Mesenchymal Stem Cells metabolism
- Abstract
Ovarian aging reduced the quality of oocytes, resulting in age-related female infertility. It is reported that mesenchymal stem cells (MSCs) therapy can improve age-related ovarian function decline and the success rate of in vitro maturation (IVM) in assisted reproductive therapy. In order to investigate the effectiveness and mechanisms of MSCs to enhance oocyte quality of cumulus oocyte complexes (COCs) in advanced age, this study focus on the respective functional improvement of oocytes and granulosa cells (GCs) from aging mice and further to explore and verify the possible mechanisms. Here, we studied a popular but significant protein of follicular development, Forkhead box O-3a (FOXO3a), which is a transcription factor that mediates a variety of cellular processes, but the functions of which in regulating oocyte quality in MSCs therapy still remain inconclusive. In this study, the RNA-seq data of metaphase II (MII) oocytes and GCs isolated from COCs confirmed that, GCs of immature follicles show the most potential to be the targeted cells of bone marrow mesenchymal stem cells (BMSCs) by FOXO3a signaling pathway. Furthermore, we demonstrated the effectiveness of BMSCs co-culture with aging COCs to enhance oocyte quality and found its mechanism to function via ameliorating the biological function of GCs by alleviating FOXO3a levels. These results provide significant fundamental research on MSCs therapy on ovarian aging, as well as offering guidance for raising the success rate of assisted reproductive technology such IVM in clinical and non-clinical settings., (© 2024. The Author(s), under exclusive licence to Society for Reproductive Investigation.)
- Published
- 2024
- Full Text
- View/download PDF